BioCardia to Participate in Upcoming Investor Conferences
BioCardia to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company’s management team will participate in the following upcoming investor conferences:
聖卡洛斯，加利福尼亞州，2021年8月13日(環球通訊社)-BioCardia®，Inc.納斯達克：BCDA)，一家治療心血管和肺部疾病的細胞和細胞衍生療法的開發商，今天宣佈，該公司的管理團隊將參加即將召開的以下投資者大會：
Q3 Investor Summit Virtual Conferencefrom August 17-18, 2021 https://investorsummitgroup.com/conferences/BioCardia Corporate Presentation scheduled for 08/17 at 2pm Eastern Time (11am Pacific time)1-1 meetings available with Company Representatives for those interested – please sign up through conference website.SNN Network Virtual Event Conferencefrom August 17-19, 2021 https://conference.snn.network/BioCardia Corporate Presentation scheduled for 08/19 at 3pm Eastern Time (12pm Pacific time)1-1 meetings available with Company Representatives for those interested – please sign up through conference website.
第三季度投資者峯會虛擬會議從2021年8月17日至18日，https://investorsummitgroup.com/conferences/BioCardia公司演示定於東部時間08/17下午2點(太平洋時間上午11點)舉行，感興趣的公司代表可參加1-1次會議-請通過會議網站報名。SNN網絡虛擬活動大會從2021年8月17日至19日，https://conference.snn.network/BioCardia公司演示定於東部時間08/19下午3點(太平洋時間下午12點)舉行，感興趣的公司代表可參加1-1次會議-請通過會議網站報名。
About BioCardia®
關於BioCardia®
BioCardia, Inc., headquartered in San Carlos, California, is a developer of two biotherapeutic platforms – the CardiAMPTMautologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogenic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases. These platforms underly four product candidates, each with the potential to meaningfully benefit millions of patients. Three of these investigational therapies are enabled by the Company’s proprietary biotherapeutic delivery platforms, which the Company also selectively licenses to other biotherapeutic development firms.
總部設在加利福尼亞州聖卡洛斯的BioCardia公司是兩種生物治療平台的開發商，一種是用於心血管適應症的心臟AMPT-Mautologous骨髓來源單核細胞療法，另一種是用於心血管和肺部疾病的NK1R+同種異體骨髓來源間充質幹細胞療法。這些平台低於四種候選產品，每種產品都有可能讓數百萬患者受益。其中三種研究療法是由該公司專有的生物治療輸送平台提供的，該公司還選擇性地將該平台授權給其他生物治療開發公司。
INVESTOR CONTACT:
投資者聯繫方式：
David McClung, Chief Financial Officer
首席財務官David McClung
investors@BioCardia.com
郵箱：Investors@BioHeara.com
(650) 226-0120
(650) 226-0120
MEDIA CONTACT:
媒體聯繫人：
Anne Laluc, Marketing
安妮·拉魯克(Anne Laluc)，市場營銷
Email: alaluc@biocardia.com
電子郵件：alaluc@biardia.com
Phone: 650-226-0120
電話：650-226-0120